In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
As the UK races to secure its position as a global leader in advanced therapies, a growing skills gap threatens to undermine billions in investment and pat...
As cell and gene therapies move rapidly from pioneering clinical trials into commercial healthcare systems the industry is facing a defining inflection poi...
Resilience is no longer a corporate slogan — it’s the new currency of survival in biopharma. As the sector races between scientific breakthroug...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
In conversation with BioPharma BoardRoom, Amanda Haupt, Business Unit Manager for Base Editing at Revvity, shares insights into how the com...
In this BioPharma Boardroom discussion, we speak with Christophe Hotermans, Head of Global Medical Affairs at Alexion, AstraZeneca Rare Disease. From the e...
Since 2019, Cytiva has committed over $1.6 billion to expand its global manufacturing capacity. In this exclusive conversation with BioPharma BoardRoom, Pi...
In this exclusive interview with BioPharma BoardRoom, Jessay Devassy, Manager, Bioprocess Applications at Ecolab Bioprocessing&...
In this exclusive interview with BioPharma BoardRoom, Mike Kadan, PhD, MBA, Chief Operating Officer of Vector BioMed, shares how the company is reimagining...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
© 2026 Biopharma Boardroom. All Rights Reserved.
